
CAS 1151516-14-1
:Formula:C17H13BrN3NaO2S
InChI:InChI=1S/C17H14BrN3O2S.Na/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14;/h1-4,7-8,10H,5-6,9H2,(H,22,23);/q;+1/p-1
InChI key:FVYMVLTWIBGEMC-UHFFFAOYSA-M
SMILES:C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)[O-].[Na+]
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Lesinurad sodium
CAS:Lesinurad sodium (RDEA594 sodium) is a selective inhibitor of uric acid reabsorption and is used in the study of cardiovascular diseases.Formula:C17H13BrN3NaO2SPurity:99.97%Color and Shape:SolidMolecular weight:426.26Sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate
CAS:Sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetateFormula:C17H13BrN3NaO2SPurity:98%Molecular weight:426.26SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETATE
CAS:Purity:98%Molecular weight:426.2600098Lesinurad sodium
CAS:Lesinurad sodium is a prodrug that is hydrolyzed to form ethyl formate, which inhibits the acid transporter (NT) in the kidneys. It is used for the treatment of chronic gouty arthritis and hyperuricemia associated with the use of xanthine oxidase inhibitors or allopurinol. Lesinurad sodium has been shown to be effective in reducing serum uric acid levels and pain symptoms in patients with chronic gouty arthritis. The drug has a plasma concentration-time curve that follows first-order kinetics and an elimination half-life of 15 hours. Lesinurad sodium has been shown to inhibit NT activity by structural formula, reaction yield, introducing techniques, and pharmacodynamics.Formula:C17H13BrN3O2S·NaPurity:Min. 95%Molecular weight:426.27 g/molAcetic acid, 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-, sodium salt (1:1)
CAS:Formula:C17H13BrN3NaO2SPurity:98%Color and Shape:SolidMolecular weight:426.2628





